fig2

Figure 2. Development of amyloid-β (Aβ)-targeted therapy for Alzheimer’s disease (AD). This figure summarizes the clinical development of Aβ-targeted pharmacotherapies for AD, reported according to the most advanced phase of the study and main therapeutic properties. Data were accessed on July 18, 2023. Agents with “*” indicate that the trials have been discontinued or are inactive. Agents with “†” indicate that the agents have been approved for the treatment of AD. Aβ: amyloid-β; AD: Alzheimer’s disease; APP: amyloid precursor protein; BACE: β-site amyloid precursor protein cleaving enzyme.